Atmosphere-ph.ru

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Лечебное дело
2018 / N 3

Терапия статинами в России: взгляд в прошлое и перспективы на ближайшее будущее
А.В. Сусеков, А.Э. Никитин

Список литературы
1. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Annals of Epidemiology 1992 Jan-Mar;2(l-2):23-8.
2. The Multiple Risk Factor Intervention Trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA 1976 Feb;235(8):825-7.
3. Keys A, Menotti A, Aravanis C, Blackburn H, Djordevič BS, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, Mohaček I, Nedeljkovič S, Puddu V, Punsar S, Henry L, Taylor HL, Conti S, Kromhout D, Toshima H. The seven countries study: 2,289 deaths in 15 years. Preventive Medicine 1984 Mar;13(2):141-54.
4. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017 Aug;38(32):2459-72.
5. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011 Jul;217(1):3-46.
6. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014 Jul;63(25 Pt B):2889-934.
7. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal 2016 Aug;37(29):2315-81.
8. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 Nov;376(9753):1670-81.
9. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012 Aug;380(9841):581-90.
10. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015 Apr;385(9976):1397-405.
11. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2×2 factorial Mendelian randomization study. Journal of American College of Cardiology 2015 Apr;65(15):1552-61.
12. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Clinical update. European Heart Journal 2018 Jul;39(27):2526-39.
13. Лякишев А.А., Кухарчук В.В., Титов В.Н., Волкова Е.И., Константинов В.О., Липовецкий Б.М., Солитернова И.Б., Дудко В.А., Канская Н.В., Крыжановский В.А. Оценка гиполипидемических эффектов ловастатина при первичной гиперхолестеринемии. Многоцентровое исследование. Кардиология 1993;33(11):48-54.
14. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov;344(8934):1383-9.
15. Сусеков А.В, Соловьева Е.Ю., Рожкова ТА, Котова ЛА, Ахмедова ЗА, Кухарчук В.В. Симвастатин при лечении больных с первичной гиперхолестеринемией: эффективность суточных доз 10-80 мг. Кардиология 2002;42(1):33-6.
16. Сусеков А.В., Соловьева Е.Ю., Котова Л.А, Кухарчук В.В. Уровень холестерина плазмы у больных с семейной гиперлипидемией после отмены высоких доз статинов. Клиническая фармакология и терапия 2002:11(4):67-70.
17. Сусеков А.В., Соловьева Е.Ю., Кухарчук В.В. Симвастатин и аторвастатин 80 мг/сут при лечении больных с наследственной гиперхолестеринемией. Клиническая фармакология и терапия 2002;11(3):12-5.
18. Сусеков А.В., Зубарева М.Ю., Рожкова Т.А., Горнякова Н.Б., Соловьева Е.Ю., Балахонова Т.В., Кулев Б.Д., Погорелова О.А., Рогоза А.Н., Бойцов С.А., Кухарчук В.В. Рандомизированное исследование ESCAPE: Зокор 20-80 мг у больных с семейной гиперхолестеринемией и ишемической болезнью сердца. Часть 1. Гиполипидемическая эффективность, безопасность и переносимость. Артериальная гипертензия 2009;15(5):543-9.
19. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 Apr;295(13):1556-65.
20. Nicholls SJ, Borgman M, Nissen SE, Raichlen JS, Ballantyne C, Barter P, Chapman MJ, Erbel R, Libby P. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Current Medical Research and Opinion 2011 Jun;27(6):1119-29.
21. Кухарчук В.В., Бубнова М.Г., Кательницкая Л.И., Никитин Ю.П., Ольбинская Л.И. Эффективность и безопасность симвастатина у пациентов с гиперхолестеринемией (результаты многоцентрового клинического исследования). Кардиология 2003;43(5):42-7.
22. Ольбинская Л.И., Данилогорская Ю.А. Эффективность, безопасность и фармакоэкономические аспекты лечения дислипидемий оригинальными и генерическими статинами. Терапевтический архив 2003;75(12):47-9.
23. Петров В.И., Недогода С.В., Сабанов А.В., Бувайлик Е.В., Цома В.В. Фармакоэкономические аспекты применения статинов при краткосрочной гиполипидемической терапии. Качественная практика 2003;1:11-5.
24. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis, Thrombosis and Vascular Biology 1995 May;15(5):678-82.
25. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). The American Journal of Cardiology 1998 Mar;81(5):582-7.
26. Andrews TC, Ballantyne CV, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. The American Journal of Medicine 2001 Aug;111(3):185-91.
27. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. The American Journal of Cardiology 2002 Mar;89(6):667-71.
28. Jones PH, McKenney JM, Karalis DG. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Evidence-based Cardiovascular Medicine 2005;9(2):98-101.
29. Schrott H, Fereshetian AG, Knopp RH, Bays H, Jones PH, Littlejohn TW 3rd, McLain R, Black DM. A multicenter, placebo-controlled, dose-ranging study of atorvastatin. Journal of Cardiovascular Pharmacology and Therapeutics 1998 Apr;3(2):119-24.
30. Haller MJ, Stein JM, Shuster JJ, Theriaque D, Samyn MM, Pepine C, Silverstein JH. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism 2009 Jan;22(1):65-8.
31. Сусеков А.В., Хохлова Н.В. Липримар. Пятнадцать лет убедительных доказательств. Рациональная фармакотерапия в кардиологии 2011;7(2):231-40.
32. Сусеков А.В. Аторвастатин в лечении гиперхолестеринемии и атеросклероза: критерии выбора дозы в различных популяциях пациентов. Атеротромбоз 2014;1:86-97.
33. Сусеков А.В., Зубарева М.Ю., Трипотень М.И., Рожкова Т.А., Погорелова О.А., Балахонова Т.В., Масенко В.П., Кухарчук В.В. Рандомизированное исследование ФАРВАТЕР Часть 1. Эффект аторвастатина 10 и 20 мг/сут на уровень липидов, С-реактивного белка и фибриногена у больных с ИБС и дислипидемией. Русский медицинский журнал 2006;14(10):1-6.
34. Сусеков А.В, Рожкова Т,А, Трипотень М.И., Погорелова О.А., Кулев Б.Д., Балахонова Т.В., Зубарева М.Ю., Масенко В.П., Рогоза А.Н., Кухарчук В.В. Рандомизированное исследование ФАРВАТЕР: Часть II. Эффект аторвастатина на функцию эндотелия, растяжимость и жесткость сосудистой стенки. Кардиоваскулярная терапия и профилактика 2007;6(3):68-75.
35. Шальнова С.А, Деев А.Д. Характеристика пациентов высокого риска. Результаты эпидемиологической части научно-образовательной программы ОСКАР. Кардиоваскулярная терапия и профилактика 2006;5(5):58-63.
36. Мареев В.Ю., Беленков Ю.Н., Оганов Р.Г., Барбик-Жагар Б. Аторвастатин в лечении пациентов с ишемической болезнью сердца и дислипидемией и высоким общим риском: оценка эффективности и безопасности. Дизайн и основные результаты исследования АТЛАНТИКА. Кардиология 2008;48(11):4-13.
37. Barbic-Žagar B, Kos J, Grošelj M. Klinicne izkušnje z atorvastatinom v visokih odmerkih. Medicinski Razgledi 2008;46(4):387-9.
38. Data on file, KRKA, d d., Novo Mesto, Slovenia, 2009.
39. Schuster H, Fox JC. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme. Expert Opinion in Pharmacotherapy 2004 May;5(5):1187-200.
40. Binbrek AS, Elis A, Al-Zaibag M, Eha J, Keber I, Cuevas AM, Mukherjee S, Miller TR; Discovery Alpha Study Group. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study). Current Therapeutic Research, Clinical and Experimental 2006 Jan;67(1):21-43.
41. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. The New England Journal of Medicine 2007 Nov;357(22):2248-61.
42. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 Nov;359(21):2195-207.
43. Чазова И.Е., Кухарчук В.В, Ратова Л.Г., Каминная В.И. Возможности гиполипидемической терапии больных артериальной гипертонией (по результатам программы "РОЗА" – РОЗувастатин у пациентов с Артериальной гипертонией). Consilium Medicum. Системные гипертензии 2006;2:23-6.
44. Зубарева М.Ю, Рожкова Т.А, Соловьева Е.Ю, Сусеков А.В. Рандомизированное исследование ЭСКАДРА. Часть 1. Гиполипидемическая эффективность, безопасность и переносимость эзетимиба, начальных доз оригинальных статинов и комбинации эзетимиба с начальными дозами статинов у больных ишемической болезнью сердца и гиперлипопротеидемией. Кардиоваскулярная терапия и профилактика 2010;9(6):74-82.
45. Smrekar J. The efficacy and safety of rosuvastatin dose titration in the treatment of patients with hyperlipidemia (ROSU-PATH). Statistical analysis report. Data on file. Krka, d. d., Novo mesto, 2014.
46. Brus S. Clinical evidence of the efficacy of Krka’s rosuvastatin in the treatment of hyperlipidemia with focus on additional doses. Krka Med Farm 2014;26(38):62-71.
47. Зубарева М.Ю., Рожкова Т.А., Амелюшкина В.А., Сусеков А.В., Кухарчук В.В. Эффективность, безопасность и переносимость терапии розувастатином 40 мг/сут у больных очень высокого сердечно-сосудистого риска с первичной гиперхолестеринемией. Результаты 24-недельного исследования 40х40. Фарматека 2013;7(260):65-8.
48. Оганов Р.Г. Сосудистая коморбидность: общие подходы к профилактике и лечению. Рациональная фармакотерапия в кардиологии 2015;11(1):4-7.
49. Оганов Р.Г., Кухарчук В.В, Арутюнов Г.П., Галявич А.С., Гуревич В.С., Дупляков Д.В., Карпов Ю.А., Кобалава Ж.Д., Константинов В.О., Марцевич С.Ю., Панов А.В., Сергиенко И.В., Скибицкий В.В., Смоленская О.Г., Сусеков А.В., Тюрин В.П., Шалаев С.В., Манешина О.А., Бригида О.В. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика 2012;11(4):70-8.
50. Ершова А.И., Мешков А.Н., Якушин С.С., Лукьянов М.М., Мосейчук К.А., Марцевич С.Ю., Загребельный А.В., Воробьев А.Н., Переверзева К.Г., Правкина Е.А., Козминский А.Н., Бойцов С.А. Диагностика и лечение больных с выраженной гиперхолестеринемией в реальной амбулаторно-клинической практике. (по данным регистра РЕКВАЗА). Рациональная фармакотерапия в кардиологии 2014;10(6):612-6.
51. Ахмеджанов Н.М., Небиеридзе Д.В., Сафарян А.С., Выгодин В.А., Шураев А.Ю., Ткачева О.Н., Лишута А.С. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО). Часть I. Рациональная фармакотерапия в кардиологии 2015;11(3):252-9.
52. Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data in Brief 2018 May;18:1937-40.
53. Fox KM, Tai MH, Kostev K, Hatz M4, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clinical Research in Cardiology 2018 May;107(5):380-8.

References
1. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Annals of Epidemiology 1992 Jan-Mar;2(l-2):23-8.
2. The Multiple Risk Factor Intervention Trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA 1976 Feb;235(8):825-7.
3. Keys A, Menotti A, Aravanis C, Blackburn H, Djordevič BS, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, Mohaček I, Nedeljkovič S, Puddu V, Punsar S, Henry L, Taylor HL, Conti S, Kromhout D, Toshima H. The seven countries study: 2,289 deaths in 15 years. Preventive Medicine 1984 Mar;13(2):141-54.
4. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017 Aug;38(32):2459-72.
5. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011 Jul;217(1):3-46.
6. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014 Jul;63(25 Pt B):2889-934.
7. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal 2016 Aug;37(29):2315-81.
8. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 Nov;376(9753):1670-81.
9. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012 Aug;380(9841):581-90.
10. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015 Apr;385(9976):1397-405.
11. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2×2 factorial Mendelian randomization study. Journal of American College of Cardiology 2015 Apr;65(15):1552-61.
12. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Clinical update. European Heart Journal 2018 Jul;39(27):2526-39.
13. Lyakishev AA, Kukharchuk VV, Titov VV, Volkova EI, Konstantinov VO, Lipovetskiy BM, Soliterova IB, Dudko VA, Kanskaya NV, Kryzhanovskiy VA. Assessment of hypolipidemic effects of lovastatin in primary hypercholesterolemia: a multicenter study. Kardiologiia 1993;33(11):48-54 (In Russian).
14. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov;344(8934):1383-9.
15. Susekov AV, Solovyeva EYu, Rozhkova TA, Kotova LA, Akhmedova ZA, Kukharchuk VV. Simvastatin in management of patients with primary hypercholesterolemia: tolerability and efficacy of 10-80 mg daily doses. Kardiologiia 2002;42(1):33-6 (In Russian).
16. Susekov AV, Solovyova EYu, Kotova LA, Kukharchuk VV. Plasma level of cholesterol in patients with familial hyperlipidemia after cancellation of high-dose statin therapy. Clinical Pharmacology and Therapy 2002:11(4):67-70 (In Russian).
17. Susekov VV, Solovyeva EYu, Kukharchuk VV. Simvastatin and atorvastatin: 80 mg/day treatment of patients with familial hypercholesterolemia. Clinical Pharmacology and Therapy 2002;11(3):12-5 (In Russian).
18. Susekov AV, Zubareva MYu, Rozhkova TA, Gornyakova NB, Solovyeva EYu, Balakhonova TV, Kulev BD, Pogorelova OA, Rogoza AN, Boytsov SA, Kukharchuk VV. The ESCAPE randomized clinical trial: 20-80 mg of Zokor (Simvastatin) in patients with familial hypercholesterolemia in ischemia heart disease. Part 1. Hypolipidemic efficacy, safety and tolerance. Arterial Hypertension 2009;15(5):543-9 (In Russian).
19. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 Apr;295(13):1556-65.
20. Nicholls SJ, Borgman M, Nissen SE, Raichlen JS, Ballantyne C, Barter P, Chapman MJ, Erbel R, Libby P. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Current Medical Research and Opinion 2011 Jun;27(6):1119-29.
21. Kukharchuk VV, Bubnova MG, Katelnitskaya LI, Nikitin YuP, Olbinskaya LI. Efficacy and safety of simvastatin in patients with hypercholesterolemia: results of a multicenter clinical study. Kardiologiia 2003;43(5):42-7 (In Russian).
22. Olbinskaya LI, Danilogorskaya YuA. Efficacy, safety, pharmacological and economic aspects of dyslipidemia treatment with original and generic statins. Therapeutic Archive 2003;75(12):47-9 (In Russian).
23. Petrov VI, Nedogoda SV, Sabanov AV, Buvaylik EV, Tsoma VV. Pharmacological and economic aspects of statin in short-term lipid-lowering therapy. Good Clinical Practice 2003;1:11-5 (In Russian).
24. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis, Thrombosis and Vascular Biology 1995 May;15(5):678-82.
25. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). The American Journal of Cardiology 1998 Mar;81(5):582-7.
26. Andrews TC, Ballantyne CV, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. The American Journal of Medicine 2001 Aug;111(3):185-91.
27. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. The American Journal of Cardiology 2002 Mar;89(6):667-71.
28. Jones PH, McKenney JM, Karalis DG. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Evidence-based Cardiovascular Medicine 2005;9(2):98-101.
29. Schrott H, Fereshetian AG, Knopp RH, Bays H, Jones PH, Littlejohn TW 3rd, McLain R, Black DM. A multicenter, placebo-controlled, dose-ranging study of atorvastatin. Journal of Cardiovascular Pharmacology and Therapeutics 1998 Apr;3(2):119-24.
30. Haller MJ, Stein JM, Shuster JJ, Theriaque D, Samyn MM, Pepine C, Silverstein JH. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism 2009 Jan;22(1):65-8.
31. Susekov AV, Khokhlova NV. Liprimar. Fifteen years of evidence. Rational Pharmacotherapy in Cardiology 2011;7(2):231-40 (In Russian).
32. Susekov AV. Atorvastatin in the treatment of hypercholesterolemia and atherosclerosis: criteria for dose selection in different patient populations. Atherothrombosis 2014;1:86-97 (In Russian).
33. Susekov AV, Zubareva MYu, Tripoten MI, Rozhkova TA, Pogorelova OA, Balakhonova TV, Masenko VP, Kukharchuk VV. The FARVATER randomized study. Part 1. Atorvastatin 10 and 20 mg/day: the effects on lipid levels, C-reactive protein and fibrinogen in patients with coronary artery disease and dyslipidemia. Russian Medical Journal 2006;14(10):1-6 (In Russian).
34. Susekov AV, Rozhkova TA, Tripoten MI, Pogorelova OA, Kulev BD, Balakhonov TV, Zubareva MYu, Masenko VP, Rogoza AN, Kukharchuk VV. The FARVATER randomized study. Part II. Atorvastatin: the effects on endothelial function, distensibility and arterial stiffness. Cardiovascular Therapy and Prevention 2007;6(3):68-75 (In Russian).
35. Shalnova SA, Deev AD. High-risk patient characteristics. The OSCAR study: results of epidemiological part. Cardiovascular Therapy and Prevention 2006;5(5):58-63 (In Russian).
36. Mareev VYu, Belenkov YuN, Oganov RG, Barbic-Žhagar B. Atorvastatin treatment in patients with ischemic heart disease, dyslipidemia and general high risk: assessment of efficacy and safety. The design and the main results of the ATLANTIC study. Kardiologiia 2008;48(11):4-13 (In Russian).
37. Barbic-Žagar B, Kos J, Grošelj M. Klinicne izkušnje z atorvastatinom v visokih odmerkih. Medicinski Razgledi 2008;46(4):387-9.
38. Data on file, KRKA, d d., Novo Mesto, Slovenia, 2009.
39. Schuster H, Fox JC. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme. Expert Opinion in Pharmacotherapy 2004 May;5(5):1187-200.
40. Binbrek AS, Elis A, Al-Zaibag M, Eha J, Keber I, Cuevas AM, Mukherjee S, Miller TR; Discovery Alpha Study Group. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study). Current Therapeutic Research, Clinical and Experimental 2006 Jan;67(1):21-43.
41. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. The New England Journal of Medicine 2007 Nov;357(22):2248-61.
42. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 Nov;359(21):2195-207.
43. Chazova IE, Kukharchuk VV, Ratova LG, Kaminnaya VI. The benefits of lipid-lowering therapy in patients with arterial hypertension: the results of the ROSA (ROSuvastatin in patients with Arterial hypertension) program. Consilium Medicum. Systemic Hypertension 2006;2:23-6 (In Russian).
44. Zubareva MYu, Rozhkova ТА, Solovyeva EYu, Susekov AV. The randomised study ESCADRA. Part I. Lipid-lowering efficacy, safety and tolerability of ezetimibe, initial doses of original statins, and the combination of ezetimibe with initial doses of statins in patients with coronary heart disease and hyperlipidemia. Cardiovascular Therapy and Prevention 2012;9(6):74-82 (In Russian).
45. Smrekar J. The efficacy and safety of rosuvastatin dose titration in the treatment of patients with hyperlipidemia (ROSU-PATH). Statistical analysis report. Data on file. Krka, d. d., Novo mesto, 2014.
46. Brus S. Clinical evidence of the efficacy of Krka’s rosuvastatin in the treatment of hyperlipidemia with focus on additional doses. Krka Med Farm 2014;26(38):62-71.
47. Zubareva MYu, Rozhkova TA, Amelyushkina VA, Susekov AV, Kukharchuk VV. Efficacy, safety and tolerance of therapy with rosuvastatin 40 mg/day in patients with a very high risk of cardiovascular disease and primary hypercholesterolemia: the results of the 24-week study 40x40. Pharmateca 2013;7(260):65-8 (In Russian).
48. Oganov RG. Vascular comorbidity: general approaches to prevention and treatment. Rational Pharmacotherapy in Cardiology 2015;11(1):4-7 (In Russian).
49. Oganov RG, Kukharchuk VV, Arutyunov GP, Galyavich AS, Gurevich VS, Duplyakov DV, Karpov YuA, Kobalava ZhD, Konstantinov VO, Martsevich SYu, Panov AV, Sergyenko IV, Skibitskiy VV, Smolenskaya OG, Susekov AV, Tyurin VP, Shalaev SV, Maneshina OA, Brigida OV. Persistent lipid spectrum disorders in patients with statin-treated dyslipidemia in clinical practice in the Russian Federation: the Russian part of the DYSIS study. Cardiovascular Therapy and Prevention 2012;11(4):70-8 (In Russian).
50. Ershova AI, Meshkov AN, Yakushin SS, Lukyanov MM, Moseychuk KA, Martsevich SYu, Zagrebelniy AV, Vorobyev AN, Pereverzeva KG, Pravkina EA, Kozminskiy AN, Boytsov SA. Diagnosis and treatment of patients with severe hypercholesterolemia in real outpatient practice: according to the RECVASA registry. Rational Pharmacotherapy in Cardiology 2014;10(6):612-6 (In Russian).
51. Akhmedzhanov NM, Nebieridze DV, Safaryan AS, Vygodin VA, Shuraev AYu, Tkacheva ON, Lishuta AS. Analysis of hypercholesterolemia prevalence in outpatient practice: according to the ARGO study. Part 1. Rational Pharmacotherapy in Cardiology 2015;11(1):252-9 (In Russian).
52. Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data in Brief 2018 May;18:1937-40.
53. Fox KM, Tai MH, Kostev K, Hatz M4, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity Statins. Clinical Research in Cardiology 2018 May;107(5):380-8.

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]